179 related articles for article (PubMed ID: 23248117)
1. Contrasting hypoxic effects on breast cancer stem cell hierarchy is dependent on ER-α status.
Harrison H; Rogerson L; Gregson HJ; Brennan KR; Clarke RB; Landberg G
Cancer Res; 2013 Feb; 73(4):1420-33. PubMed ID: 23248117
[TBL] [Abstract][Full Text] [Related]
2. Distinct breast cancer stem/progenitor cell populations require either HIF1α or loss of PHD3 to expand under hypoxic conditions.
Iriondo O; Rábano M; Domenici G; Carlevaris O; López-Ruiz JA; Zabalza I; Berra E; Vivanco Md
Oncotarget; 2015 Oct; 6(31):31721-39. PubMed ID: 26372732
[TBL] [Abstract][Full Text] [Related]
3. Genome-independent hypoxic repression of estrogen receptor alpha in breast cancer cells.
Padró M; Louie RJ; Lananna BV; Krieg AJ; Timmerman LA; Chan DA
BMC Cancer; 2017 Mar; 17(1):203. PubMed ID: 28320353
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer.
Schwab LP; Peacock DL; Majumdar D; Ingels JF; Jensen LC; Smith KD; Cushing RC; Seagroves TN
Breast Cancer Res; 2012 Jan; 14(1):R6. PubMed ID: 22225988
[TBL] [Abstract][Full Text] [Related]
5. Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α.
Barone I; Brusco L; Gu G; Selever J; Beyer A; Covington KR; Tsimelzon A; Wang T; Hilsenbeck SG; Chamness GC; Andò S; Fuqua SA
J Natl Cancer Inst; 2011 Apr; 103(7):538-52. PubMed ID: 21447808
[TBL] [Abstract][Full Text] [Related]
6. Cyclin A1 modulates the expression of vascular endothelial growth factor and promotes hormone-dependent growth and angiogenesis of breast cancer.
Syed Khaja AS; Dizeyi N; Kopparapu PK; Anagnostaki L; Härkönen P; Persson JL
PLoS One; 2013; 8(8):e72210. PubMed ID: 23991063
[TBL] [Abstract][Full Text] [Related]
7. Loss of Mel-18 enhances breast cancer stem cell activity and tumorigenicity through activating Notch signaling mediated by the Wnt/TCF pathway.
Won HY; Lee JY; Shin DH; Park JH; Nam JS; Kim HC; Kong G
FASEB J; 2012 Dec; 26(12):5002-13. PubMed ID: 22954590
[TBL] [Abstract][Full Text] [Related]
8. CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer.
Conley SJ; Baker TL; Burnett JP; Theisen RL; Lazarus D; Peters CG; Clouthier SG; Eliasof S; Wicha MS
Breast Cancer Res Treat; 2015 Apr; 150(3):559-67. PubMed ID: 25833208
[TBL] [Abstract][Full Text] [Related]
9. Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells.
Hao L; Rizzo P; Osipo C; Pannuti A; Wyatt D; Cheung LW; Sonenshein G; Osborne BA; Miele L
Oncogene; 2010 Jan; 29(2):201-13. PubMed ID: 19838210
[TBL] [Abstract][Full Text] [Related]
10. Oestrogen increases the activity of oestrogen receptor negative breast cancer stem cells through paracrine EGFR and Notch signalling.
Harrison H; Simões BM; Rogerson L; Howell SJ; Landberg G; Clarke RB
Breast Cancer Res; 2013 Mar; 15(2):R21. PubMed ID: 23497505
[TBL] [Abstract][Full Text] [Related]
11. CARM1 is an important determinant of ERα-dependent breast cancer cell differentiation and proliferation in breast cancer cells.
Al-Dhaheri M; Wu J; Skliris GP; Li J; Higashimato K; Wang Y; White KP; Lambert P; Zhu Y; Murphy L; Xu W
Cancer Res; 2011 Mar; 71(6):2118-28. PubMed ID: 21282336
[TBL] [Abstract][Full Text] [Related]
12. ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models.
Brooks DL; Schwab LP; Krutilina R; Parke DN; Sethuraman A; Hoogewijs D; Schörg A; Gotwald L; Fan M; Wenger RH; Seagroves TN
Mol Cancer; 2016 Mar; 15():26. PubMed ID: 27001172
[TBL] [Abstract][Full Text] [Related]
13. HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways.
Yan Y; Liu F; Han L; Zhao L; Chen J; Olopade OI; He M; Wei M
J Exp Clin Cancer Res; 2018 Oct; 37(1):256. PubMed ID: 30340507
[TBL] [Abstract][Full Text] [Related]
14. The inhibitory effect of hypoxic cytotoxin on the expansion of cancer stem cells in ovarian cancer.
Nozawa-Suzuki N; Nagasawa H; Ohnishi K; Morishige K
Biochem Biophys Res Commun; 2015 Feb; 457(4):706-11. PubMed ID: 25619133
[TBL] [Abstract][Full Text] [Related]
15. Impact of hypoxia inducible factors on estrogen receptor expression in breast cancer cells.
Wolff M; Kosyna FK; Dunst J; Jelkmann W; Depping R
Arch Biochem Biophys; 2017 Jan; 613():23-30. PubMed ID: 27823907
[TBL] [Abstract][Full Text] [Related]
16. Anti-cancer stem cell activity of a hedgehog inhibitor GANT61 in estrogen receptor-positive breast cancer cells.
Kurebayashi J; Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T
Cancer Sci; 2017 May; 108(5):918-930. PubMed ID: 28211214
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-induced secretion stimulates breast cancer stem cell regulatory signalling pathways.
Jacobsson H; Harrison H; Hughes É; Persson E; Rhost S; Fitzpatrick P; Gustafsson A; Andersson D; Gregersson P; Magnusson Y; Ståhlberg A; Landberg G
Mol Oncol; 2019 Aug; 13(8):1693-1705. PubMed ID: 31066211
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological Inhibition of MCT4 Reduces 4-Hydroxytamoxifen Sensitivity by Increasing HIF-1α Protein Expression in ER-Positive MCF-7 Breast Cancer Cells.
Nadai T; Narumi K; Furugen A; Saito Y; Iseki K; Kobayashi M
Biol Pharm Bull; 2021; 44(9):1247-1253. PubMed ID: 34471053
[TBL] [Abstract][Full Text] [Related]
19. GPER mediates the angiocrine actions induced by IGF1 through the HIF-1α/VEGF pathway in the breast tumor microenvironment.
De Francesco EM; Sims AH; Maggiolini M; Sotgia F; Lisanti MP; Clarke RB
Breast Cancer Res; 2017 Dec; 19(1):129. PubMed ID: 29212519
[TBL] [Abstract][Full Text] [Related]
20. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
